home / stock / bcli / bcli news

BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 04/09/24

Stock Information
Company Name: Brainstorm Cell Therapeutics Inc.
Stock Symbol: BCLI
Market: NASDAQ
Website: brainstorm-cell.com
Menu
BCLI BCLI Quote BCLI Short BCLI News BCLI Articles BCLI Message Board
Get BCLI Alerts

News, Short Squeeze, Breakout and More Instantly...
BCLI - BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy

2024-04-09 06:58:24 ET More on BrainStorm Cell Therapeutics BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial ...
BCLI - BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS PR Newswire Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK , April 9, 2024 /PRNewswire/ -- BrainStorm Cell T...

BCLI - BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program PR Newswire A conference call and webcast will be held Tomorrow, April 9 , at 8:00 a.m. Eastern Time NEW YORK , April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: B...

BCLI - BrainStorm Cell Therapeutics GAAP EPS of -$0.40 beats by $0.16

2024-04-01 08:44:27 ET More on BrainStorm Cell Therapeutics BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial ...
BCLI - BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update PR Newswire Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK , April 1, 2024 /PRNewswire/ -- BrainStorm Cel...

BCLI - US Companies Moving the Markets, Evening edition
Wed, Mar 20, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) rose 0.1% to $0.1331 on volume of 235,074,479 shares Jaguar Health Inc. (JAGX) rose 16.0% to $0.0799 on volume of 189,600,392 shares BYND Cannasoft Enterprises Inc. (BCAN) rose 2.5% to $0.0205 on volume of 17...

BCLI - BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference PR Newswire Planned Phase 3b trial Designed to Confirm Efficacy and Safety of NurOwn in mild-to-moderate ALS patients NEW YORK , Feb. 2...
BCLI - BrainStorm submits SPA request to FDA for Phase 3 study design

2024-02-23 13:24:46 ET More on BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics spikes on patent wins Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial information ...

BCLI - BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS PR Newswire NEW YORK , Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ste...

BCLI - BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum

BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum PR Newswire NEW YORK , Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disea...
Previous 10 Next 10